Loading clinical trials...
Loading clinical trials...
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN, LOCAL TOLERABILITY AND DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE-DOSE, TOPICAL ADMINISTRATION OF PF-07038124 TO HEALTHY PARTICIPANTS
Conditions
Interventions
PF-07038124 and Vehicle
PF-07038124 or vehicle
+5 more
Locations
1
United States
Pfizer New Haven Clinical Research Unit
New Haven, Connecticut, United States
Start Date
October 29, 2019
Primary Completion Date
April 10, 2020
Completion Date
April 10, 2020
Last Updated
May 14, 2020
NCT05769777
NCT06192563
NCT03687359
NCT03992417
NCT05983068
NCT06015308
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions